secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORASURE TECHNOLOGIES INC (OSUR)
CIK:        0001116463
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0000950170-22-016137
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OraSure Q2 revenue record $80.2M (+39% YoY) but GAAP EPS ($0.26); InteliSwab sales surge 95% QoQ
--------------------------------------------------------------------------------

- GAAP net loss of $18.8M vs. $1.4M loss in Q2 2021; gross margin fell to 34.4% from 53.2%.
- Non-GAAP gross margin improved 250 bps sequentially to 40.1%; non-GAAP EPS ($0.00).
- Q3 revenue guidance $90-95M (67-76% YoY growth); expects positive cash flow by Q4 2022.
- Appointed Ken McGrath as CFO effective Aug 8; three directors resign Nov 8; Mara Aspinall to become Board Chair.
- InteliSwab capacity now ~1.6M tests/week, expected to nearly double by early 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1116463/000095017022016137/0000950170-22-016137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1116463/000095017022016137/osur-20220809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer